Archive · 29 Jul 2026
India poised to lead genomics revolution
India is in a great spot to lead the way in genomics, which is the study of genes and DNA.
This is because many patents on important medicines are about to expire, creating a big opportunity.
India has a lot of experience making medicines and is now getting better at making more advanced treatments like biologics and gene therapies.
The country is also using AI to speed up the process of discovering new drugs.
This is part of a bigger trend where companies are investing a lot of money in biotech, and India is well-positioned to take advantage of this.
India is poised to lead the genomics revolution due to its strong pharmaceutical manufacturing base and growing capabilities in biologics, gene therapies, and precision oncology.
A $300 billion patent expiry wave presents a massive growth opportunity for Indian manufacturers.
AI is compressing drug discovery timelines from a decade to under 18 months, making India a potential hub for accelerated biopharma development.
Biopharma M&A reached $106 billion in the first half of 2026, on pace for the strongest full year since pre-pandemic.
India's domestic genomics market is growing at over 16% annually, with initiatives like the Genome India Project mapping 10,000 genomes across 99 ethnic groups.
- Who
- India, Vallum Capital, WHO-certified pharmaceutical manufacturers
- What
- India's potential to lead the genomics revolution amid a global patent expiry wave
- When
- 2026
- Where
- India, Global
- Why
- Due to the patent expiry wave, growing capabilities in biologics, gene therapies, and precision oncology, and the use of AI in drug discovery
Optimistic View
Cautious View
India's Position in Global Genomics
Optimistic View
India is uniquely positioned to capitalize on the genomics revolution due to its strong pharmaceutical manufacturing base and growing capabilities in biologics, gene therapies, and precision oncology.
Cautious View
While India has potential, significant investments and infrastructure development are still needed to fully capitalize on the genomics revolution.
Patent Expiry Opportunities
Optimistic View
The $300 billion patent expiry wave presents a massive growth opportunity for Indian manufacturers, especially in biologics and gene therapies.
Cautious View
The patent expiry wave may bring competition, but Indian manufacturers need to ensure they have the necessary capabilities to compete effectively.
AI and Drug Discovery
Optimistic View
AI is significantly compressing drug discovery timelines, making India a potential hub for accelerated biopharma development.
Cautious View
While AI shows promise, its integration into drug discovery is still evolving, and its long-term impact remains to be seen.
- Patent Expiry Wave
- $300 billion
- Biopharma M&A in 2026 (H1)
- $106 billion
- Biotech IPOs in 2026 (H1)
- More than entire 2025
- Venture Capital in Biotech (2025)
- $38 billion
- India's Genomics Market Growth
- Over 16% annually
- Genome India Project
- Mapping 10,000 genomes across 99 ethnic groups